Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Bullboard Posts
Post by JordanDeeon Feb 21, 2018 7:16am
135 Views
Post# 27592396

news 😊 I think we are about to get a news flow!

news 😊 I think we are about to get a news flow! First Ventripoint Whole Heart System Operational at University of Alberta Mazankowski Heart Institute (via TheNewswire) Toronto, Canada / TheNewswire / February 21, 2018 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT) is pleased to announce the installation of the VMS+ whole heart analysis system at the University of Alberta Mazankowski Alberta Heart Institute under the supervision of Dr. Jonathan Windram, Staff Cardiologist, Northern Alberta Adult Congenital Heart Program and Associate Clinical Professor of Medicine, Division of Cardiology, Department of Medicine, University of Alberta Mazankowski Alberta Heart Institute. "We look forward to beginning new clinical studies that will utilize Ventripoint's new multiple chamber analysis capabilities," stated Dr. Windram. "We are pleased that the VMS+ is operational at Mazankowski and look forward to the results from two innovative clinical studies that will highlight the increased abilities of the VMS+ to analyze the heart and improve patient care," commented Desmond Hirson, President of Ventripoint. "Better diagnoses for all cardiac patients, especially children, is why we work so hard to improve the VMS+." About the Mazankowski Alberta Heart Institute (Mazankowski) Mazankowski is the advanced cardiac care center for Edmonton, Northern and North-Central Alberta, Northern BC, Saskatchewan, Manitoba, Yukon and Northwest Territories. Located on the Walter C. Mackenzie Health Sciences Centre Campus in Edmonton, Mazankowski is physically integrated with the University of Alberta and Stollery Children's Hospitals, making it one of the very few heart institutes to accommodate both adult and pediatric patients. The Mazankowski has one of the most technologically advanced Echo Labs in the world providing leading-edge imaging techniques such as 3D, contrast, myocardial perfusion, speckle tracking and interventional echo. About Ventripoint Diagnostics Ltd. Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR) to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care. For Further Information, Contact: Dr. George Adams, CEO T: 519-803-6937 E: gadams@ventripoint.com
Bullboard Posts